• Facebook
  • Twitter
  • Linkedin
  • Vimeo
AMF
  • Home
  • About
    • Leading Us into the Future
    • People of AMF
    • Alfred Mann
    • History
      • Our History Timeline
      • Dr. Joe Schulman
    • Events
      • AMF Awards
      • Fundraising Galas
  • Patient Stories
  • Innovations
    • Research
      • Neuromuscular Disorders
      • Diabetes
      • Limb Loss
      • Chronic Pain
    • Patents
    • Publications
    • Commercialization
  • Incubator
    • Concept To Commercialization
    • Services
    • Equipment
    • Space Available
    • Partners
  • Media
    • Videos
    • News
  • Careers
    • Company Culture
    • Join Our Team
    • Life in Santa Clarita
  • Please Donate
  • Search
  • Menu
  • 1985

     

    Alfred Mann Foundation Founded

    Alfred Mann Foundation established to bridge basic research in medicine and to create products that filled unmet and poorly-met needs.

  • 1986

     

    Clarion® Cochlear Implant

    Together with the University of California San Francisco and The Research Triangle Institute, AMF works on the enabling technology for what will become the Clarion® Cochlear Implant.

  • 1989

     

    Neurostimulator

    In collaboration with the Illinois Institute of Technology (IIT) and Queens University in Canada, AMF begins development of a miniature implantable neurostimulator device. AMF works on the hermetically sealed case, IIT on circuitry, and Queens on communication protocol.

  • 1991

     

    Microstimulator

    AMF and its partners deliver the first prototype of the implantable microstimulator device, which is powered and controlled using radio frequency (RF) and is encased in a glass capsule. A subsequent iteration of the RF-powered microstimulator (RFM) employs a stronger hermetic casing made of ceramic.

  • 1993

     

    Advanced Bionics Formed

    Advanced Bionics is formed and receives the license to manufacture and distribute the Clarion® Cochlear Implant.

  • 1996

     

    MRG Formed

    Medical Research Group (MRG) is formed to work on the long-term glucose sensor, one of AMF’s founding projects.

  • 1998

     

    Alfred E. Mann Institute for Biomedical Engineering at USC established

  • 1999

     

    BPM Implant

    AMF begins development of a battery-powered microstimulator (BPM) implant, which will have a rechargeable battery, and high-speed two-way telemetry.

  • 2001

     

    BION® Developed

    AMF licenses microstimulator technology to Advanced Bionics for certain medical applications. Advanced Bionics develops a battery-powered microstimulator device called BION®, which is used in clinical trials for urinary incontinence. Boston Scientific later obtains this license and develops a BION® application to treat migraine headache.

  • 2003

     

    IMES

    AMF, Illinois Institute of Technology and the Rehabilitation Institute of Chicago form a partnership to develop an Implantable MyoElectric Sensor (IMES) system that could be used to control prosthetic limbs.

    RFM Clinical Trials

    2003-2005 – clinical trials with the RF microstimulator (RFM) device are conducted in applications relating to obstructive sleep apnea, shoulder subluxation, and post-stroke upper limb hemiplegia.

  • 2004

     

    Bioness, Inc

    Bioness, Inc. is established and granted a license to use technology for rehabilitation applications.

  • 2006

     

    Alfred Mann Institute at the Technion established

  • 2008

     

    RFM Clinical Trials

    2008-2009 – AMF pursues clinical trials with the RFM on lower limb applications for patients with stroke and spinal cord injuries.

  • 2010

     

    Infusion Systems, Inc.

    Infusion Systems, Inc. and its implantable drug delivery technology is acquired by AMF.

  • 2011

     

    RFM Clinical Trials

    Clinical trials with the RFM are planned for patients suffering from dysphagia as a result of head and neck cancer and for patients with upper limb hemiplegia as a result of traumatic brain injury.

    Infusion Systems

    Clinical trials with the Infusion Systems drug delivery system are launched for patients with back pain.

  • 2013

     

    Axonics spin-out

  • 2014

     

    Medallion Therapeutics spin-out

     Monolythix spin-out

  • 2017

     

    Axonics receives IDE clearance from the FDA for a Pivotal Study of the Treatment of Urinary Dysfunction

  • 2018

     

    Axonics receives CE mark • Axonics IPO • Axonics files for Premarket Approval

  • 2019

     

    Axonics IDE study results showing a 90% response rate are published in the Journal of Urology

  • 2019

     

    Össur and Alfred Mann Foundation Sign New Agreement to Extend Exploration of Mind-Controlled Prosthetics

PreviousNext
Copyright © 2019 - AMF
  • Terms of use
  • Privacy
  • Copyright
  • Legal
Scroll to top
Show Buttons
Hide Buttons